{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T12:41:44Z","timestamp":1753274504028},"reference-count":10,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,4,1]]},"DOI":"10.2169\/internalmedicine.8411-21","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T22:14:38Z","timestamp":1648764878000},"page":"933-934","source":"Crossref","is-referenced-by-count":1,"title":["Galectin-3 as an Arrhythmogenic Predictive Marker for Heart Failure"],"prefix":"10.2169","volume":"61","author":[{"given":"Keiko","family":"Inoue","sequence":"first","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Tajiri","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Makimoto H, M\u00fcller P, Denise K, et al. Clinical impact of circulating galectin-3 on ventricular arrhythmias and heart failure hospitalization independent of prior ventricular arrhythmic events in patients with implantable cardioverter-defibrillators. Intern Med 61: 969-977, 2022.","DOI":"10.2169\/internalmedicine.7886-21"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Lau ES, Liu E, Paniagua SM, et al. Galectin-3 inhibition with modified citrus pectin in hypertension. JACC Basic to Transl Sci 6: 12-21, 2021.","DOI":"10.1016\/j.jacbts.2020.10.006"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. De Boer RA, Van Der Velde AR, Mueller C, et al. Galectin-3: A modifiable risk factor in heart failure. Cardiovasc Drugs Ther 28: 237-246, 2014.","DOI":"10.1007\/s10557-014-6520-2"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Sharma UC, Pokharel S, Van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110: 3121-3128, 2004.","DOI":"10.1161\/01.CIR.0000147181.65298.4D"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. De Boer RA, Voors AA, Muntendam P, Van Gilst WH, Van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 11: 811-817, 2009.","DOI":"10.1093\/eurjhf\/hfp097"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60: 1249-1256, 2012.","DOI":"10.1016\/j.jacc.2012.04.053"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ghorbani A, Bhambhani V, Christenson RH, et al. Longitudinal change in galectin-3 and incident cardiovascular outcomes. J Am Coll Cardiol 72: 3246-3254, 2018.","DOI":"10.1016\/j.jacc.2018.09.076"},{"key":"8","first-page":"e1054","volume":"135","author":"SL Chow","year":"2017","unstructured":"8. Chow SL, Maisel AS, Anand I, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation 135: e1054-e1091, 2017.","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Brouwers FP, Van Gilst WH, Damman K, et al. Clinical risk stratification optimizes value of biomarkers to predict new-onset heart failure in a community-based cohort. Circ Hear Fail 7: 723-731, 2014.","DOI":"10.1161\/CIRCHEARTFAILURE.114.001185"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sharma A, Felker GM. Challenges and opportunities in the evaluation of nutraceuticals in cardiovascular diseases. JACC Basic Transl Sci 6: 22-24, 2021.","DOI":"10.1016\/j.jacbts.2020.12.008"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/7\/61_8411-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T03:44:43Z","timestamp":1648871083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/7\/61_8411-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8411-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"article-number":"8411-21"}}